As one of four referral centers in the country for amyloid diseases, the Division of Rheumatology at Mount Sinai has significant clinical and research expertise in these conditions. Current basic research is examining the pathogensis of various forms of amyloid disease, especially those associated with aging and heredofamilial forms of amyloidosis.
Clinical trials run in the division include evaluation of novel therapies for secondary (reactive) amyloidosis, auto-inflammatory diseases, heredofamilial, and age-related amyloidosis. The division is also active in clinical trials for novel therapies for cryoglobulinemias and extrahepatic manifestations of chronic hepatitis C virus (HCV) infection.
Mount Sinai has been a recognized center in gout therapeutics since the 1950s, stemming from the original contributions of Drs. Alexander Gutman and Tsai-Fan Yu. Their findings led to the introduction of probenecid for treating gout and to the discovery of the potential of colchicine for preventing attacks of gout. Tophacceous gout is increasing in frequency as incidences of metabolic syndrome and renal failure increase as well as a side effect of post organ transplantation medications. Current studies are focused on the use of drugs that lower uric acid, such as recombinant uricase for patients with advanced tophaceous disease